New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options

New Horizons in Myeloproliferative Neoplasms Treatment: A Review of Current and Future Therapeutic Options

Philadelphia-negative myeloproliferative neoplasms (MPN) are aggressive diseases characterized by clonal proliferation of myeloid stem cells. The clonal process leads to excessive red cells production, platelets production, and bone marrow fibrosis. According to the phenotype, MPN can be classified...

Full description

Bibliographic Details
Main Author:	Domenico Penna
Format:	Article
Language:	English
Published:	MDPI AG 2021-10-01
Series:	Medicina
Subjects:	essential thrombocythemia myelofibrosis myeloproliferative neoplasms Polycythemia vera treatment
Online Access:	https://www.mdpi.com/1648-9144/57/11/1181

Similar Items

Real-world status of treatment for lymphoid neoplasms developed during the course of myeloproliferative neoplasms in Japan
by: Yoko Edahiro, et al.
Published: (2024-12-01)

The Power of Extracellular Vesicles in Myeloproliferative Neoplasms: “Crafting” a Microenvironment That Matters
by: Lucia Catani, et al.
Published: (2021-09-01)

Mechanisms of platelet activation in cancer-associated thrombosis: a focus on myeloproliferative neoplasms
by: Roelof H. Bekendam, et al.
Published: (2023-06-01)

Pediatric Philadelphia-Negative Myeloproliferative Neoplasms in the Era of WHO Classification: A Systematic Review
by: Abdulrahman F. Al-Mashdali, et al.
Published: (2023-01-01)

Synergic Crosstalk between Inflammation, Oxidative Stress, and Genomic Alterations in BCR–ABL-Negative Myeloproliferative Neoplasm
by: Alessandro Allegra, et al.
Published: (2020-10-01)

A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms
by: Tarinee Rungjirajittranon, et al.
Published: (2019-02-01)

Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada
by: Jonathan Heppner, et al.
Published: (2019-05-01)

Impact of Myeloproliferative neoplasms on patients’ employment status and work productivity in the United States: results from the living with MPNs survey
by: Jingbo Yu, et al.
Published: (2018-04-01)

Smoking is associated with increased risk of myeloproliferative neoplasms: A general population‐based cohort study
by: Kasper M. Pedersen, et al.
Published: (2018-11-01)

Primary Arterial Hypertension and Drug-Induced Hypertension in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
by: Mihnea-Alexandru Găman, et al.
Published: (2023-01-01)

Clinical and molecular profile of a Brazilian cohort of patients with classical BCR-ABL1-negative myeloproliferative neoplasms
by: Moysés Antonio Porto-Soares, et al.
Published: (2020-07-01)

Recent insights regarding the molecular basis of myeloproliferative neoplasms
by: Mi-Ae Jang, et al.
Published: (2020-01-01)

Liquid Biopsy and Potential Liquid Biopsy-Based Biomarkers in Philadelphia-Negative Classical Myeloproliferative Neoplasms: A Systematic Review
by: Mihnea-Alexandru Găman, et al.
Published: (2021-07-01)

Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm
by: Ik-Chan Song, et al.
Published: (2021-09-01)

Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications—A Narrative Review
by: Samuel Bogdan Todor, et al.
Published: (2024-08-01)

The 2020 revision of the guidelines for the management of myeloproliferative neoplasms
by: Sung-Yong Kim, et al.
Published: (2021-01-01)

Clinical features of children with polycythemia vera, essential thrombocythemia, and primary myelofibrosis in Japan: A retrospective nationwide survey
by: Hisashi Ishida, et al.
Published: (2020-07-01)

Integration of Molecular Information in Risk Assessment of Patients with Myeloproliferative Neoplasms
by: Giuseppe G. Loscocco, et al.
Published: (2021-08-01)

The Approach to Thrombosis Prevention across the Spectrum of Philadelphia-Negative Classic Myeloproliferative Neoplasms
by: Steffen Koschmieder
Published: (2021-06-01)

A REVIEW OF BCR ABL1 NEGATIVE MYELOPROLIFERATIVE NEOPLASM WITH DENTAL IMPLICATIONS
by: Madhura Bhatt
Published: (2022-01-01)

The ruxolitinib effect: understanding how molecular pathogenesis and epigenetic dysregulation impact therapeutic efficacy in myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2018-12-01)

Myeloproliferative blood cancers as a human neuroinflammation model for development of Alzheimer’s disease: evidences and perspectives
by: Hans C. Hasselbalch, et al.
Published: (2020-08-01)

Molecular biology of Philadelphia-negative myeloproliferative neoplasms
by: Paulo Vidal Campregher, et al.
Published: (2012-01-01)

Janus kinase inhibitors: jackpot or potluck?
by: Pavithran Keechilat, et al.
Published: (2012-06-01)

Thrombosis in myeloproliferative neoplasms: A clinical and pathophysiological perspective
by: Sarah Kelliher, et al.
Published: (2021-12-01)

Comparison of molecular genetic methods of detection of mutations in the CALR gene in myeloproliferative disorders
by: L. A. Kesaeva, et al.
Published: (2019-07-01)

Philadelphia-negative chronic myeloproliferative neoplasms
by: Rosane Isabel Bittencourt, et al.
Published: (2012-01-01)

Histopathology imagery dataset of Ph-negative myeloproliferative neoplasm
by: Umi Kalsom Mohamad Yusof, et al.
Published: (2023-10-01)

Evaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
by: Marko Lucijanic, et al.
Published: (2024-04-01)

Evaluation of thrombin generation in classical Philadelphianegative myeloproliferative neoplasms / Evaluarea generării trombinei în neoplasmele mieloproliferative Philadelphia- negative
by: Olteanu Ariela Ligia, et al.
Published: (2016-09-01)

BCR::ABL1-negative myeloproliferative neoplasms in the era of next-generation sequencing
by: Aleksandra Mroczkowska-Bękarciak, et al.
Published: (2023-09-01)

Mutations, inflammation and phenotype of myeloproliferative neoplasms
by: Sylvie Hermouet, et al.
Published: (2023-05-01)

Evaluation of the Relationship between Janus Kinase 2 Mutational Burden and Clinical Findings in Adult Myeloproliferative Neoplasm Patients
by: Cigdem Yuce Kahraman, et al.
Published: (2022-01-01)

Molecular pathogenesis of the myeloproliferative neoplasms
by: Graeme Greenfield, et al.
Published: (2021-06-01)

NEW APPROACHES TO THERAPY OF CLASSICAL PH-NEGATIVE MYELOPROLIFERATIVE DISEASES: THE EXPERIENCE OF EARLY THERAPY WITH CEPEGINTERFERON ALPHA-2B
by: A. S. Polyakov, et al.
Published: (2018-05-01)

Elevated Vitamin B12 Levels in Myeloproliferative Neoplasm (MPN) Patients: A Potential Diagnostic and Prognostic Marker
by: Fadul A, et al.
Published: (2024-12-01)

Systematization of analytical studies of polycythemia vera, essential thrombocythemia and primary myelofibrosis, and a meta-analysis of the frequency of JAK2, CALR and MPL mutations: 2000–2018
by: Mónica Mejía-Ochoa, et al.
Published: (2019-06-01)

C-Mannosyl tryptophan is a novel biomarker for thrombocytosis of myeloproliferative neoplasms
by: Shotaro Tabata, et al.
Published: (2024-08-01)

Clinical and laboratory presentations of Janus Kinase II-positive patients in Saudi population
by: H Malhan, et al.
Published: (2014-01-01)

Chronic myeloproliferative disorders: A rarest case with oral manifestations and dental management
by: Pritesh B Ruparelia, et al.
Published: (2012-01-01)